Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) fell 3.6% during mid-day trading on Tuesday . The company traded as low as $7.10 and last traded at $7.45, with a volume of 1,186,901 shares. The stock had previously closed at $7.73.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, May 31st. Maxim Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a report on Wednesday, May 11th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd.

The company’s market cap is $272.11 million. The stock’s 50-day moving average is $4.88 and its 200-day moving average is $4.76.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its quarterly earnings data on Wednesday, May 11th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.10. On average, analysts predict that Anavex Life Sciences Corp. will post ($0.34) EPS for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.